Glioma

Results of p53 Gene Therapy Trial in Recurrent Cancer are Encouraging

Published in Gene Therapy Weekly, September 21st, 2000

Preliminary results from a Phase I clinical trial of p53 gene therapy for recurrent glioma are encouraging, researchers in the United States report.

"Conventional treatments of human gliomas have achieved limited success," stated Frederick F. Lang and colleagues from the M.D. Anderson Cancer Center, Texas, the University of California, and the North American Brain Tumor Consortium.

"Preclinical studies have suggested that transfer of the p53 gene using an adenovirus vector (Ad-p53, RPR/INGN 201) may be clinically applicable in gliomas. Consequently, a Phase I clinical trial of Ad-p53 for recurrent gliomas was undertaken in order to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-09-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry